罕见上皮性卵巢癌人群统计演变
基于SEER 1988-2016年113,365例卵巢恶性肿瘤的回顾性观察研究,比较透明细胞癌、黏液性癌和低级别浆液性癌与高级别浆液性癌的生存。早期期别罕见癌预后与高级别浆液性癌相当或更优,但晚期透明细胞癌和黏液性癌生存更差,且5年生存率未改善。
要点
- 透明细胞癌和黏液性癌早期诊断比例高于高级别浆液性癌。
- 晚期透明细胞癌和黏液性癌总生存劣于高级别浆液性癌。
- 晚期高级别浆液性癌和低级别浆液性癌5年生存率改善,而透明细胞癌和黏液性癌未改善。
核心结论
- 透明细胞癌、黏液性癌和低级别浆液性癌占卵巢恶性肿瘤2-7%,生物学特征和生存不同于高级别浆液性癌。
- 早期罕见癌预后良好或相当,但晚期透明细胞癌和黏液性癌生存 disproportionately 差,需新治疗策略。
研究设计与样本
- 回顾性观察研究,使用SEER数据库1988-2016年数据。
- 共纳入113,365例卵巢恶性肿瘤,其中透明细胞癌5780例(5.1%)、黏液性癌7561例(6.7%)、低级别浆液性癌2021例(1.8%),与38,199例高级别浆液性癌比较。
- 采用倾向性评分匹配比较总生存。
主要发现
- 透明细胞癌和黏液性癌诊断时I期比例分别为57.0-59.5%,高级别浆液性癌为8.6%(P<0.001)。
- 早期疾病中,透明细胞癌(HR 0.91,95%CI 0.82-1.01)和黏液性癌(HR 0.94,95%CI 0.85-1.04)总生存与高级别浆液性癌相似,低级别浆液性癌更优(HR 0.93,95%CI 0.89-0.97)。
- 晚期疾病中,透明细胞癌(HR 1.42,95%CI 1.32-1.53)和黏液性癌(HR 1.11,95%CI 1.09-1.13)总生存更差,低级别浆液性癌更优(HR 0.86,95%CI 0.84-0.89)。
- 诊断后前3年,透明细胞癌(HR范围1.92-2.45)和黏液性癌(HR范围1.73-2.22)总生存尤其差。
- 晚期疾病5年总生存率:高级别浆液性癌从16.9%升至36.8%(P<0.001),低级别浆液性癌从50.8%升至66.4%(P=0.010);透明细胞癌(21.0%至28.2%,P=0.174)和黏液性癌(21.4%至16.5%,P=0.102)无变化。
临床怎么用
- 临床应认识到罕见上皮性卵巢癌与高级别浆液性癌生存差异,晚期透明细胞癌和黏液性癌预后尤其差。
- 对晚期透明细胞癌和黏液性癌需探索新型治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe how population-based statistics for rare epithelial ovarian cancers are evolving. METHODS: This is a retrospective observational study examining the Surveillance, Epidemiology, and End Results Program from 1988 to 2016. Overall survival (OS) of clear cell (OCCC), mucinous (MOC), and low-grade serous (LGSOC) ovarian cancers were compared to high-grade serous ovarian cancer (HGSOC) by fitting a propensity score matching. RESULTS: Among 113,365 ovarian malignancies, 5780 OCCCs (5.1%), 7561 MOCs (6.7%), and 2021 LGSOCs (1.8%) were compared to 38,199 HGSOCs. OCCCs and MOCs were more likely to be diagnosed with stage I disease compared to HGSOC (57.0-59.5% versus 8.6%, P<0.001). For early-stage disease, OCCC (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.82-1.01) and MOC (HR 0.94, 95%CI 0.85-1.04) had similar OS to HGSOC whereas LGSOC had superior OS (HR 0.93, 95%CI 0.89-0.97) versus HGSOC. Conversely, for advanced-stage disease, OCCC (HR 1.42, 95%CI 1.32-1.53) and MOC (HR 1.11, 95%CI 1.09-1.13) had poorer OS whereas LGSOC (HR 0.86, 95%CI 0.84-0.89) had superior OS compared to HGSOC. OCCC (HR range, 1.92-2.45) and MOC (HR range, 1.73-2.22) had particularly poorer OS in the first three years following diagnosis compared to HGSOC. Population-level statistics for advanced-stage disease showed that 5-year OS rates have increased in HGSOC (16.9% to 36.8%, P<0.001) and LGSOC (50.8% to 66.4%, P=0.010); but remain unchanged for OCCC (21.0% to 28.2%, P=0.174) and MOC (21.4% to 16.5%, P=0.102). CONCLUSION: OCCC, MOC, and LGSOC comprise 2-7% of ovarian malignancies, have distinct characteristics and survival compared to HGSOC. While these rare tumors have a favorable to comparable prognosis in early-stage disease, disproportionally poor survival in advanced-stage OCCC and MOC highlights the need for further research into novel treatment strategies.
引用
- Matsuo K, Machida H, Matsuzaki S, et al. Evolving population-based statistics for rare epithelial ovarian cancers. Gynecol Oncol. 2020. PMID: 31954534. doi:10.1016/j.ygyno.2019.11.122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。